TABLE 1.
BASELINE CHARACTERISTICS OF STUDY PARTICIPANTS
| Symptom Monitoring (n = 147) | Peak Flow Monitoring (n = 149) | Total (n =296) | |
|---|---|---|---|
| Female sex, % | 52 | 52 | 52 |
| White/non-Hispanic race, % | 94 | 95 | 94 |
| Age, mean, yr (SD) | 66 (9.2) | 66 (9.6) | 66 (9.4) |
| Asthma duration, median, yr (IQR) | 20 (11–42) | 19 (10–48) | 20 (10–44) |
| Smoking status, % | |||
| Never-smoker | 33 | 41 | 37 |
| Current smoker | 7 | 3 | 5 |
| Ex-smoker | 59 | 56 | 57 |
| Pack-years of smoking, median (IQR)* | 19 (0–41) | 4 (0–35) | 9 (0–38) |
| Prevalence of atopic symptoms,† % | 93 | 94 | 93 |
| Daily inhaled corticosteroid use, % | 90 | 89 | 90 |
| No. daily breathing meds, median (IQR) | 2 (0–6) | 2 (0–6) | 2 (0–6) |
| No. comorbidities,‡ median (IQR) | 1 (0–4) | 1 (0–5) | 1 (0–5) |
| Prealbuterol FEV1, mean, % predicted (SD) | 58.5 (22.0) | 59.4 (21.7) | 58.9 (21.8) |
| % Change in FEV1 in response to albuterol | 16.3 (12.6) | 17.1 (20.4) | 17.1 (17.0) |
Definition of abbreviation: IQR = interquartile range (25th to 75th percentiles).
*
Limited to ever-smokers.
†
Atopic symptoms defined as a positive response to questions about hay fever, or coughing, wheezing, chest tightness, or shortness of breath when near animals, feathers, dust, trees, grasses, or pollens.
‡
Comorbidities include physician-diagnosed chronic obstructive pulmonary disease, cardiovascular or nervous system diseases, insulin-dependent diabetes, and mental illness requiring medication.